Research ArticleBasic Science Investigations
Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses
Jacob L. Houghton, Brian M. Zeglis, Dalya Abdel-Atti, Ritsuko Sawada, Wolfgang W. Scholz and Jason S. Lewis
Journal of Nuclear Medicine March 2016, 57 (3) 453-459; DOI: https://doi.org/10.2967/jnumed.115.163824
Jacob L. Houghton
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York
Brian M. Zeglis
3Department of Chemistry, Hunter College and the Graduate Center of the City University of New York, New York, New York; and
Dalya Abdel-Atti
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York
Ritsuko Sawada
4MabVax Therapeutics, San Diego, California
Wolfgang W. Scholz
4MabVax Therapeutics, San Diego, California
Jason S. Lewis
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 3
March 1, 2016
Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses
Jacob L. Houghton, Brian M. Zeglis, Dalya Abdel-Atti, Ritsuko Sawada, Wolfgang W. Scholz, Jason S. Lewis
Journal of Nuclear Medicine Mar 2016, 57 (3) 453-459; DOI: 10.2967/jnumed.115.163824
Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses
Jacob L. Houghton, Brian M. Zeglis, Dalya Abdel-Atti, Ritsuko Sawada, Wolfgang W. Scholz, Jason S. Lewis
Journal of Nuclear Medicine Mar 2016, 57 (3) 453-459; DOI: 10.2967/jnumed.115.163824
Jump to section
Related Articles
Cited By...
- 212Pb-Pretargeted Theranostics for Pancreatic Cancer
- Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
- The Future of Nuclear Medicine, Molecular Imaging, and Theranostics
- Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy
- Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors
- Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry
- Pretargeted Immuno-PET: Overcoming Limitations of Space and Time